DORAL, Florida, June 07, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, as well as research and development, is pleased to share updates on its ongoing CBD formula patents and medical device progress.
In March 2018 the Company announced it had received a grant from the Government of Quebec to develop its three new cannabinoid-based products. The prototyping of the three CBD formula patents has begun at CDBQ. The first batch will be tested by the team, and in vitro testing will begin in summer 2019 to show the superior antioxidant activities and better anti-proliferative effects on breast cancer cells. The stability tests will be done over a 1-year period. The third product, which is a superfood edible, will be ready for Q4 of 2018. The branding of these unique products is currently in the planning stage. It is anticipated that these original products, made from high quality ingredients, will achieve great success since their function is to maintain quality of life, prevent inflammation, cancer and degenerative diseases.
Earth Science Tech also shares its progress in the launch of the MSN-2 medical device and finalization of the last step before large scale deployment. The company is working with Accélération, Design et Innovation Inc. (ADI Hardware Accelerator). The final packaging will have a great look that women – the target market - will appreciate. Our partners from Djibouti, Morocco, Vietnam, and the Middle East can’t wait to see and test our new medical device which is dedicated to improving the health of women in their countries and around the world.
The Company’s CEO and Chief Science Officer, Dr. Michel Aubé stated, “The official launch of this medical device is a little like giving birth. It will be unique in the marketplace and we are branding this device globally. The commercial name will be announced soon, as we are in the process of trademark protection for the logo and name. We will create a strong demand for this medical device by showing the world its powerful capacity to diminish the prevalence of chlamydia and other Sexually Transmitted Infections.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, and studies through DV Biologics proved it lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets, and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:
Earth Science Pharmaceutical
Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharma, Inc. ("ESP"), which is committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer Dr. Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics
Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs.
To learn more please visit: www.CannabisThera.com
KannaBidioiD
KannaBidioid, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioiD, Inc. (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.
To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Earth Science Foundation, Inc. ("ESF"), is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech, Inc's effective CBD products to those in need.
To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.